GREGORY VIDAL, M.D
Medical Oncology Physician · GERMANTOWN, TN
Individual Active NPI 1730403072
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 768 | 144,187 | $11,729,117 | $3,210,399 | $2,562,459 |
| 2023 | 531 | 33,825 | $2,894,942 | $837,837 | $667,589 |
| 2022 | 628 | 18,911 | $1,611,114 | $445,027 | $356,716 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12,160 | $3 | $2 |
| J9271 | Injection, pembrolizumab, 1 mg | 11,000 | $56 | $45 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 9,750 | $1 | $1 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 9,700 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 5,322 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 4,320 | $50 | $40 |
| J0897 | Injection, denosumab, 1 mg | 3,960 | $24 | $20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,296 | $0 | $0 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 2,930 | $26 | $21 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 2,112 | $24 | $19 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 850 | $1 | $1 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 725 | $4 | $4 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 51775 | TN |
| Medical Oncology Physician | 207RX0202X | 23969 | MS |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Tennessee
- NPI 1336147263
- NPI 1083801450
- NPI 1578548376
- NPI 1902420268
- NPI 1295778330
- NPI 1053340802
- NPI 1902838964
- NPI 1750313631
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.